荷爾蒙避孕藥市場規模、佔有率和成長分析：按產品類型、給藥途徑、荷爾蒙類型、年齡層、最終用戶和地區分類－2026-2033年產業預測

2024 年全球荷爾蒙避孕藥市場價值為 178.4 億美元，預計到 2025 年將成長至 186.1 億美元，到 2033 年將成長至 260.6 億美元，在預測期（2026-2033 年）內複合年成長率為 4.3%。

全球荷爾蒙避孕藥市場正經歷顯著成長，這主要得益於對有效避孕措施需求的不斷成長、女性使用率的提高以及生殖健康意識提升的增強。約82%的育齡女性使用某種形式的避孕措施，其中許多人使用多種方法。絕大多數（約85%）女性使用避孕措施是為了避免懷孕，而其他人則是出於健康原因或預防性性行為感染。諸如「避孕措施取得舉措」和印度的「國家計劃生育計畫」等措施正在改善荷爾蒙避孕藥的可及性，並進一步推動市場成長。此外，對地索高諾酮等新型避孕藥的持續投入，擴大了可供選擇的避孕藥種類，也促進了市場的成長趨勢。

全球荷爾蒙避孕藥市場成長要素

全球荷爾蒙避孕藥市場正受到計劃生育意識增強和女性教育程度提高的顯著推動。這一趨勢在促進現代避孕方法的普及方面發揮著至關重要的作用，尤其是在中低收入國家，因為改善生殖健康的努力正在不斷加強。隨著越來越多的女性了解自身選擇，包括注射避孕藥和口服避孕藥在內的荷爾蒙避孕藥的使用量持續成長。人們對計劃生育重要性的日益重視，促使全球對荷爾蒙避孕藥的需求和接受度不斷提高，這反映出社會正在發生更廣泛的轉變，即賦予女性更多自主選擇權。

全球荷爾蒙避孕藥市場面臨的限制因素

全球荷爾蒙避孕藥市場面臨嚴峻挑戰，這主要歸因於中東、南亞和撒哈拉以南非洲部分地區根深蒂固的文化規範、宗教保守主義和父權結構。在這些地區，未婚女性和青少年往往遭受社會歧視和社區批評，嚴重限制了她們獲得醫療保健的機會。這種阻力不僅限制了個人選擇，也抑制了對荷爾蒙避孕藥的整體需求，阻礙了市場成長和擴張。克服這些障礙需要社會變革和加強生殖權利與健康的教育。

全球荷爾蒙避孕藥市場趨勢

全球荷爾蒙避孕藥市場正經歷顯著的變化趨勢，這主要得益於避孕行業的快速數字轉型。基於應用程式的處方箋服務和遠端醫療的興起，提高了藥物的可及性和便利性，尤其受到重視隱私和易用性的千禧世代和Z世代消費者的青睞。醫療服務提供者也擴大採用這些數位化平台，以簡化處方箋管理、追蹤用藥依從性並改善諮詢服務。這項創新不僅提高了用藥依從性，也提升了使用者滿意度，反映出醫療解決方案正朝著更貼合科技達人不斷變化的偏好的方向發展。因此，這一趨勢正在塑造荷爾蒙避孕藥的未來。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球荷爾蒙避孕藥市場規模：依產品類型分類

• 口服避孕藥
• 避孕貼片
• 植入式桿
• 避孕環
• 避孕器（IUD）
• 注射式避孕藥
• 事後緊急避孕藥

全球荷爾蒙避孕藥市場規模：依給藥途徑分類

• 口服
• 經皮
• 陰道內部
• 皮下

全球荷爾蒙避孕藥市場規模：依荷爾蒙類型分類

• 複雜荷爾蒙
• 單獨使用黃體素

全球荷爾蒙避孕藥市場規模：依年齡層別分類

• 18-25歲
• 26-35歲
• 36歲以上

全球荷爾蒙避孕藥市場規模：依最終用戶分類

• 家
• 醫院
• 診所

全球荷爾蒙避孕藥市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• AbbVie
• Bayer
• Pfizer Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Johnson & Johnson
• Organon Group
• HRA Pharma
• Afaxys, Inc.
• Agile Therapeutics
• GlaxoSmithKline plc
• Dr. Reddy's Laboratories Ltd.
• Theramex
• Cupid Limited
• Lupin Pharmaceuticals, Inc.
• Novartis AG
• Piramal Enterprises Ltd.
• Ferring Pharmaceuticals
• Aimmune Therapeutics

結論與建議

Global Hormonal Contraceptives Market size was valued at USD 17.84 Billion in 2024 and is poised to grow from USD 18.61 Billion in 2025 to USD 26.06 Billion by 2033, growing at a CAGR of 4.3% during the forecast period (2026-2033).

The global market for hormonal contraceptives is experiencing significant growth driven by rising demand for effective birth control methods, high usage rates among women, and increased awareness of reproductive health. Approximately 82% of women of reproductive age utilize some form of contraception, with many employing multiple methods. A large majority, around 85%, seek to prevent pregnancy, while others utilize contraceptives for medical conditions or to prevent sexually transmitted infections. Initiatives like the Contraceptive Access Initiative and the National Family Planning Program in India enhance accessibility to hormonal contraceptives, further propelling market growth. Additionally, ongoing funding efforts for new contraceptive options, such as desogestrel, continue to expand the landscape of available choices, contributing to the market's upward trajectory.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormonal Contraceptives market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hormonal Contraceptives Market Segments Analysis

Global Hormonal Contraceptives Market is segmented by Product Type, Route of Administration, Hormone Type, Age Group, End User and region. Based on Product Type, the market is segmented into Oral Contraceptives, Contraceptive Patch, Implantable Rod, Vaginal Ring, Intrauterine Device (IUD), Injectable Birth Control and Emergency Contraceptive Pills. Based on Route of Administration, the market is segmented into Oral, Transdermal, Intravaginal and Subdermal. Based on Hormone Type, the market is segmented into Combined Hormone and Progestin Only. Based on Age Group, the market is segmented into 18-25 Years, 26-35 Years and 36+ Years. Based on End User, the market is segmented into Household, Hospitals and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hormonal Contraceptives Market

The global market for hormonal contraceptives is significantly driven by heightened awareness of family planning and the increasing levels of education among women. This trend has been essential in promoting access to modern contraceptive methods, particularly in middle- and low-income countries, where initiatives focused on improving reproductive health are gaining momentum. As more women become informed about their options, the usage of hormonal contraceptive methods, including injectables and oral pills, continues to rise. This growing recognition of the importance of family planning contributes to the expanding demand and acceptance of hormonal contraceptives worldwide, reflecting a broader shift towards empowering women in their reproductive choices.

Restraints in the Global Hormonal Contraceptives Market

The global market for hormonal contraceptives faces significant challenges due to deeply entrenched cultural norms, religious conservatism, and patriarchal structures prevalent in regions like the Middle East, South Asia, and parts of Sub-Saharan Africa. In these areas, unmarried women and adolescents often grapple with societal stigma and community judgment, which severely restrict their ability to access reproductive healthcare. This resistance limits not only individual choice but also the overall demand for hormonal contraceptives, thereby impeding the market's potential for growth and expansion. Overcoming these barriers requires social change and enhanced education around reproductive rights and health.

Market Trends of the Global Hormonal Contraceptives Market

The Global Hormonal Contraceptives market is witnessing a significant trend driven by the rapid digital transformation within the contraceptive industry. The emergence of app-based prescription services and telemedicine is enhancing accessibility and convenience, particularly for millennial and Gen Z consumers who prioritize privacy and user-friendliness. Healthcare providers are increasingly adopting these digital platforms to streamline prescription management, track compliance, and improve consultations. This innovation not only boosts adherence rates but also elevates user satisfaction, reflecting a shift towards integrated healthcare solutions that cater to the evolving preferences of a tech-savvy population. Consequently, this trend is shaping the future of hormonal contraceptives.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Hormonal Contraceptives Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Oral Contraceptives
• Contraceptive Patch
• Implantable Rod
• Vaginal Ring
• Intrauterine Device (IUD)
• Injectable Birth Control
• Emergency Contraceptive Pills

Global Hormonal Contraceptives Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Transdermal
• Intravaginal
• Subdermal

Global Hormonal Contraceptives Market Size by Hormone Type & CAGR (2026-2033)

• Market Overview
• Combined Hormone
• Progestin Only

Global Hormonal Contraceptives Market Size by Age Group & CAGR (2026-2033)

• Market Overview
• 18-25 Years
• 26-35 Years
• 36+ Years

Global Hormonal Contraceptives Market Size by End User & CAGR (2026-2033)

• Market Overview
• Household
• Hospitals
• Clinics

Global Hormonal Contraceptives Market Size & CAGR (2026-2033)

• North America (Product Type, Route of Administration, Hormone Type, Age Group, End User)
  • US
  • Canada
• Europe (Product Type, Route of Administration, Hormone Type, Age Group, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Route of Administration, Hormone Type, Age Group, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Route of Administration, Hormone Type, Age Group, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Route of Administration, Hormone Type, Age Group, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HRA Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Afaxys, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agile Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theramex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cupid Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aimmune Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations